Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eculizumab exemplifies a more extreme case. It binds human complement component C5 with high affinity but does not cross-react with rodent C5. Conventional rodent PK and pharmacology studies are therefore essentially uninformative regarding target engagement.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [53]
Citations
Cites
1 retracted
The structure of complement C3b provides insights into complement activation and regulation
Ajees, A. A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V. L., Kotwal, G. J., & Murthy, H. M. K. (2006) · Nature · doi:10.1038/nature05258 · Cited by 70
RetractedHematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91481-4 · Cited by 1,437
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11367.x · Cited by 1,164
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Research works printed but not linked: 4
- Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
- Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
- Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
- Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
Cited by
Items 101–200 of 780
Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view
Luzzatto, L., Gianfaldoni, G., & Notaro, R. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08690.x · Cited by 102
“Eculizumab is a humanized (originally murine) monoclonal antibody specific for the C5 component of human complement (Rother et al, 2007).”
BackgroundThe REGAIN study group, Vissing, J., Jacob, S., Fujita, K. P., O’Brien, F., & Howard, J. F. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09770-y · Cited by 109
An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document
Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyo, J. M., Macia, M. L., Mendizábal, S., Praga, M., et al. (2015) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2015.11.006 · Cited by 100
Variability and Action Mechanism of a Family of Anticomplement Proteins in Ixodes ricinus
Couvreur, B., Beaufays, J., Charon, C., Lahaye, K., Gensale, F., Denis, V., Charloteaux, B., Decrem, Y., Prévôt, P.-P., Brossard, M., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001400 · Cited by 100
“For instance, the anti-C5 humanized antibody or eculizumab which inhibits the generation of both C5b and anaphylatoxin C5a is currently tested in clinical studies against autoimmune inflammatory diseases such as rheumatoid arthritis, glomerulonephritis and lupus erythematosus and has recently been shown to be effectiv…”
BackgroundComplement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria
Lin, Z., Schmidt, C. Q., Koutsogiannaki, S., Ricci, P., Risitano, A. M., Lambris, J. D., & Ricklin, D. (2015) · Blood · doi:10.1182/blood-2015-02-625871 · Cited by 99
Grevys, A., Bern, M., Foss, S., Bratlie, D. B., Moen, A., Gunnarsen, K. S., Aase, A., Michaelsen, T. E., Sandlie, I., & Andersen, J. T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401218 · Cited by 95
Advances in assay of complement function and activation
Harboe, M., Thorgersen, E. B., & Mollnes, T. E. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.010 · Cited by 105
“A somatic mutation with loss of the glycolipid anchor and the membrane protective CD55 and CD59 proteins leads to paroxysmal nocturnal hemoglobinuria (PNH) [50].”
BackgroundNew concepts on the therapeutic control of complement anaphylatoxin receptors
Hawksworth, O. A., Li, X. X., Coulthard, L. G., Wolvetang, E. J., & Woodruff, T. M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.05.015 · Cited by 95
“…for all inflammatory diseases, with no significant efficacy observed in trials for the treatment of macular degeneration, rheumatoid arthritis, or in improving transplant and coronary bypass outcomes (Verrier et al., 2004; Rother et al., 2007; Garcia Filho et al., 2014; Yehoshua et al., 2014).”
BackgroundStructural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus
Laursen, N. S., Gordon, N., Hermans, S. J., Lorenz, N., Jackson, N. P., Wines, B. D., Spillner, E., Christensen, J. B., Jensen, M., Fredslund, F., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910565107 · Cited by 98
“Eculizumab, a humanizedmonoclonal antibody for the treatment of PNH that prevents C5 cleavage, is the first complement inhibitor approved by the FDA and EMEA (13).”
BackgroundDevelopments in anti-complement therapy; from disease to clinical trial
Harris, C. L., Pouw, R. B., Kavanagh, D., Sun, R., & Ricklin, D. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.06.008 · Cited by 91
Detection of complement activation using monoclonal antibodies against C3d
Thurman, J. M., Kulik, L. N., Orth, H. N., Wong, M., Renner, B., Sargsyan, S. A., Mitchell, L. M., Hourcade, D. E., Hannan, J. P., Kovacs, J. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65861 · Cited by 98
Cyclosporine Induces Endothelial Cell Release of Complement-Activating Microparticles
Renner, B., Klawitter, J., Goldberg, R. J., McCullough, J. W., Ferreira, V. P., Cooper, J. E., Christians, U., & Thurman, J. M. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012111064 · Cited by 91
Inhibition of complement in Guillain‐Barré syndrome: the ICA‐GBS study
Davidson, A. I., Halstead, S. K., Goodfellow, J. A., Chavada, G., Mallik, A., Overell, J. R., Lunn, M. P., McConnachie, A., van Doorn, P. A., & Willison, H. J. (2016) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12194 · Cited by 91
“It is a humanised anti-C5 neutralising antibody which prevents the formation of membrane attack complex (MAC) (Rother et al., 2007).”
BackgroundTargeting complement components C3 and C5 for the retina: Key concepts and lingering questions
Kim, B. J., Mastellos, D. C., Li, Y., Dunaief, J. L., & Lambris, J. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100936 · Cited by 88
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
Gatault, P., Brachet, G., Ternant, D., Degenne, D., Récipon, G., Barbet, C., Gyan, E., Gouilleux‐Gruart, V., Contin‐Bordes, C., Farrell, A., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1086049 · Cited by 93
Nanomedicine and the complement paradigm
Moghimi, S. M., & Farhangrazi, Z. S. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.02.011 · Cited by 89
New milestones ahead in complement-targeted therapy
Ricklin, D., & Lambris, J. D. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.06.001 · Cited by 89
Bonte, L. R. L., Pavlov, V. I., Tan, Y. S., Takahashi, K., Takahashi, M., Banda, N. K., Zou, C., Fujita, T., & Stahl, G. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102916 · Cited by 89
“erythematosus (14), biomaterial-associated thrombosis (15), and paroxysmal nocturnal hemoglobinuria (16), to name just a few.”
BackgroundAtypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab
Servais, A., Devillard, N., Frémeaux‐Bacchi, V., Hummel, A., Salomon, L. J., Contin‐Bordes, C., Gomer, H., Legendre, C. M., & Delmas, Y. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw314 · Cited by 91
“The Fc portionof eculizumabisahybridof IgG4andIgG2[17],andthelatter is lessproneto cross the placenta [18], presumably minimizing foetal exposure.”
BackgroundComplement activation and disease: protective effects of hyperbilirubinaemia
Basiglio, C. L., Arriaga, S. M. M., Pelusa, F., Almará, A. M., Kapitulnik, J., & Mottino, A. D. (2009) · Clinical Science · doi:10.1042/cs20080540 · Cited by 90
Anand, B. G., Dubey, K., Shekhawat, D. S., & Kar, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-10911-z · Cited by 89
Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
Wong, E. K. S., Goodship, T. H. J., & Kavanagh, D. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.05.224 · Cited by 98
“Eculizumab is a recombinant, monoclonal antibody directed gainst human complement component C5 (Rother et al., 2007). unology 56 (2013) 199–212”
BackgroundInfluentialRöth, A., Rottinghaus, S. T., Hill, A., Bachman, E. S., Kim, J. S., Schrezenmeier, H., Terriou, L., Urbano-Ispizúa, Á., Wells, R. A., Jang, J. H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020644 · Cited by 89
Novel Strategies in Immunosuppression: Issues in Perspective
Webber, A. B., Hirose, R., & Vincenti, F. G. (2011) · Transplantation · doi:10.1097/tp.0b013e3182145306 · Cited by 90
“The second agent is eculizumab, the humanized anti-C5 antibody, currently Food and Drug Administration approved for the treatment of paroxysmal nocturnal hemoglobinuria (47).”
BackgroundRavulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
Stern, R. M., & Connell, N. T. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719874728 · Cited by 92
Kulasekararaj, A. G., Risitano, A. M., Maciejewski, J. P., Notaro, R., Browett, P., Lee, J. W., Huang, M., Geffner, M., & Brodsky, R. A. (2021) · Blood · doi:10.1182/blood.2021011388 · Cited by 84
Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside
Pu, J. J., & Brodsky, R. A. (2011) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00262.x · Cited by 84
Mantegazza, R., Wolfe, G. I., Muppidi, S., Wiendl, H., Fujita, K. P., O’Brien, F., Booth, H., Howard, J. F., Mazia, C. G., Wilken, M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011207 · Cited by 83
“In most patients with myasthenia gravis (MG), the disease is managed using immunosuppressive therapies (ISTs); however, 10%–15% of patients do not respond adequately to ISTs, experience intolerable adverse events, or require maintenance IV immunoglobulin or plasma exchange treatment.1–3 These patients are considered t…”
BackgroundAdvancing therapeutic complement inhibition in hematologic diseases: PNH and beyond
Gavriilaki, E., de Latour, R. P., & Risitano, A. M. (2021) · Blood · doi:10.1182/blood.2021012860 · Cited by 98
Kim, S. I., Noh, J., Kim, S., Choi, Y., Yoo, D. K., Lee, Y., Lee, H., Jung, J., Kang, C. K., Song, K.-H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd6990 · Cited by 81
Immunoglobulin isotype knowledge and application to Fc engineering
Brezski, R. J., & Georgiou, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.002 · Cited by 99
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Substrate recognition by complement convertases revealed in the C5–cobra venom factor complex
Laursen, N. S., Andersen, K. R., Braren, I., Spillner, E., Sottrup‐Jensen, L., & Andersen, G. R. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.341 · Cited by 83
Zwarthoff, S. A., Berends, E. T. M., Mol, S., Ruyken, M., Aerts, P. C., Józsi, M., de Haas, C. J. C., Rooijakkers, S. H. M., & Gorham, R. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01691 · Cited by 90
“The inhibitors include naturally occurring complement inhi bitors derived from humans [C3b-binders CRIg (31, 32), FH (33, 34), and FHR5 (35)], bacteria [homologous C3b-binders Efb-C (36) and Ecb (16, 23) and C5-binder SSL7 (37)], and ticks [C5-binder OmCI (20)], or therapeutic inhibitors eculizumab [Soliris, a clinica…”
BackgroundBadri, P. S., Jiang, X., Borodovsky, A., Najafian, N., Kim, J. B., Clausen, V. A., Goel, V., Habtemariam, B. A., & Robbie, G. J. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00940-9 · Cited by 86
Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors
Yadav, M. K., Maharana, J., Yadav, R., Saha, S., Sarma, P., Soni, C., Singh, V., Saha, S., Ganguly, M., Li, X. X., et al. (2023) · Cell · doi:10.1016/j.cell.2023.09.020 · Cited by 86
Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood
Mantovani, S., Gordon, R., Macmaw, J. K., Pfluger, C. M., Henderson, R. D., Noakes, P. G., McCombe, P., & Woodruff, T. M. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.09.005 · Cited by 86
“This is a potential avenue for future clinical testing either with existing antibodies such as eculizumab, or specific C5aR antagonists (Rother et al., 2007; Woodruff et al., 2011).”
BackgroundParoxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
Risitano, A. M. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.014 · Cited by 83
Current and future treatment approaches for neuromyelitis optica
Collongues, N., & Seze, J. D. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611398939 · Cited by 85
“Its use has been validated for the treatment of paroxysmal nocturnal hemoglobinuria, in which erythrocyte lysis results from improper complement regulation [Rother et al. 2007].”
MethodThurman, J. M., & Nester, C. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01710216 · Cited by 81
“The loss of CR1 may permit C activation at this location, or it may be a consequence of C5b-9 formation (66).”
BackgroundInfluentialWong, E. K. S., & Kavanagh, D. (2014) · Translational research · doi:10.1016/j.trsl.2014.10.010 · Cited by 82
“Development of an anti-C5 antibody began by screening murine monoclonal immunoglobulin (IgG) that bound to human C5 for the capability to block C5a generation and complement mediated cell lysis via MAC (7).”
InfluentialComplement Inhibitor Therapy for Myasthenia Gravis
Albazli, K., Kaminski, H. J., & Howard, J. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00917 · Cited by 76
“All have targeted C5 with the goal of blocking terminal complement activation, preventing the pro-inflammatory effects of C5a and C5b and the subsequent formation of the terminal Frontiers in Immunology | www.frontiersin.org 4 June 2020 | Volume 11 | Article 917 complement component or membrane attack complex (C5b-9)…”
MethodInfluentialMcKeage, K. (2011) · Drugs · doi:10.2165/11208300-000000000-00000 · Cited by 76
“In patients with PNH, eculizumab inhibits terminal complement mediated intravascular haemolysis.([13]) The components 0 10 20 30 40 50 60 70 80”
InfluentialRiedl, M., Thorner, P. S., & Licht, C. P. B. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3310-4 · Cited by 93
Role of complement and perspectives for intervention in ischemia-reperfusion damage
Banz, Y., & Rieben, R. (2012) · Annals of Medicine · doi:10.3109/07853890.2010.535556 · Cited by 76
How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future
Risitano, A. M., & de Latour, R. P. (2021) · British Journal of Haematology · doi:10.1111/bjh.17753 · Cited by 82
“Treatment options for haemolytic PNH remained limited and often inadequate until the availability of eculizumab, a humanized monoclonal antibody (mAb) targeting component 5 (C5) of the complement cascade.(28) By disabling the complement cascade at the level of the terminal complement (i.”
BackgroundSmart polymers in drug delivery: a biological perspective
Hunter, A. C., & Moghimi, S. M. (2017) · Polymer Chemistry · doi:10.1039/c6py00676k · Cited by 84
Milani, M., Annoni, A., Bartolaccini, S., Biffi, M., Russo, F., Di Tomaso, T., Raimondi, A., Lengler, J., Holmes, M. C., Scheiflinger, F., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708148 · Cited by 72
“Complement-mediated LV inactivation was overcome by adding eculizumab, a humanized monoclonal antibody that binds complement protein C5 (Fig 3D; Rother et al, 2007; Legendre et al, 2013).”
BackgroundSoluble Membrane Attack Complex: Biochemistry and Immunobiology
Barnum, S. R., Bubeck, D., & Schein, T. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585108 · Cited by 84
Kanakura, Y., Ohyashiki, K., Shichishima, T., Okamoto, S., Ando, K., Ninomiya, H., Kawaguchi, T., Nakao, S., Nakakuma, H., Nishimura, J., et al. (2011) · International Journal of Hematology · doi:10.1007/s12185-010-0748-9 · Cited by 72
Risitano, A. M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4118-2_10 · Cited by 76
Risitano, A. M. (2008) · Biologics · doi:10.2147/btt.s1420 · Cited by 71
“1-mAb, Soliris ® , Alexion Pharmaceuti-cals) is a humanized monoclonal antibody (mAb) (Figure 4) derived from the murine anti-human C5 mAb (Rother et al 2007).”
Aleshin, A. E., DiScipio, R. G., Stec, B., & Liddington, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.361121 · Cited by 73
“They include inflammation caused by trauma (49), rheumatoid arthritis (50), macular degeneration (51, 52), hemolytic anemias (53, 54), nephritis (55, 56), and demyelinating neuropathies such as multiple sclerosis and Guillain-Barré syndrome (57, 58).”
Backgroundde Latour, R. P., Brodsky, R. A., Ortiz, S. R., Risitano, A. M., Jang, J. H., Hillmen, P., Kulagin, A., Kulasekararaj, A. G., Rottinghaus, S. T., Aguzzi, R., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16711 · Cited by 76
“Steady-state therapeutic serum concentrations of ravulizumab were achieved after the first ravulizumab dose, with a greater than four-times longer mean (SD) terminal half-life observed in ravulizumab-treated patients across both studies [49 7 (8 9) days] (Alexion Pharmaceuticals 12/2018) compared with the previously r…”
ResultComplement cascade in severe forms of COVID‐19: Recent advances in therapy
Benmansour, N. C., Carvelli, J., & Vivier, É. (2021) · European Journal of Immunology · doi:10.1002/eji.202048959 · Cited by 69
Harnessing Fc receptor biology in the design of therapeutic antibodies
Sondermann, P., & Szymkowski, D. E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.005 · Cited by 77
Barratt‐Due, A., Pischke, S. E., Nilsson, P. H., Espevik, T., & Mollnes, T. E. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3vmr0316-132r · Cited by 73
“activation (IgG4 portion; Table 1) [17].”
BackgroundAutoantibody-mediated diseases of the CNS: Structure, dysfunction and therapy
Varley, J. A., Taylor, J., & Irani, S. R. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.046 · Cited by 77
“Eculizumab prevents the generation of C5a, and the proinflammatory and cytolytic effects of terminal complement activation (Rother et al., 2007).”
Current treatment of atypical hemolytic uremic syndrome
Kaplan, B. S., Ruebner, R. L., Spinale, J. M., & Copelovitch, L. A. (2014) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2014.01001 · Cited by 74
Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics
Patriquin, C. J., & Kuo, K. H. M. (2019) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2019.09.004 · Cited by 75
Self-Assembly of Artificial Sweetener Aspartame Yields Amyloid-like Cytotoxic Nanostructures
Anand, B. G., Prajapati, K. P., Dubey, K., Ahamad, N., Shekhawat, D. S., Rath, P. C., Joseph, G. K., & Kar, K. (2019) · ACS Nano · doi:10.1021/acsnano.9b02284 · Cited by 69
Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria
Dezern, A. E., Dorr, D., & Brodsky, R. A. (2012) · European Journal Of Haematology · doi:10.1111/ejh.12021 · Cited by 68
“After an initial 1-month loading period, the drug is administered intravenously every 14 ± 2 d. Eculizumab blocks terminal complement activation by recognizing C5 and preventing formation of the MAC (11, 12).”
BackgroundInfluentialPlaque complement activation and cognitive loss in Alzheimer's disease
Loeffler, D. A., Camp, D. M., & Bennett, D. A. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-9 · Cited by 68
“A trial in AD patients with an inhibitor of late-stage complement activation such as Eculizumab (Soliris, Alexion Pharmaceuticals) [49], a humanized anti-C5 monoclonal antibody which prevents formation of C5b-9, might also help to resolve this issue.”
BackgroundQu, H., Magotti, P., Ricklin, D., Wu, E. L., Kourtzelis, I., Wu, Y., Kaznessis, Y. N., & Lambris, J. D. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.10.004 · Cited by 72
Advances and challenges in therapeutic monoclonal antibodies drug development
dos Santos, M. L., Quintilio, W., Manieri, T. M., Tsuruta, L. R., & Moro, A. M. (2018) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902018000001007 · Cited by 80
“Sci. 2018;54(Special):e01007 5 mAbs, representing 80.3% of mAbs currently in clinical use, followed by IgG4 (12.7%), IgG2 (5.6”
BackgroundInfluentialComplement serves as a switch between CD4+ T cell–independent and –dependent RBC antibody responses
Mener, A., Patel, S. R., Arthur, C. M., Chonat, S., Wieland, A., Santhanakrishnan, M., Liu, J., Maier, C. L., Jajosky, R. P., Girard‐Pierce, K. R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121631 · Cited by 67
“As activation of the complement cascade can lead to the downstream generation of C5 (59), and C5 has been shown to play a significant role in CD4+ T cell activation, costimulation, as well as survival (60, 61), whether C5 is important in the development of a CD4+ T cell–independent anti-KEL antibody response was next…”
BackgroundDeveloping Treatments for Chronic Kidney Disease in the 21st Century
Breyer, M. D., & Suszták, K. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.08.001 · Cited by 75
Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0147-7 · Cited by 65
“It binds to the complement protein C5 with high affinity (Kd of 120 pmol/L), inhibiting the cleavage of C5 to C5a (a potent proinflammatory mediator) and C5b, thereby preventing the generation of the terminal complement complex C5b-9 and blocking complement-mediated thrombotic microangiopathy [14, 17, 36, 37].”
BackgroundParoxysmal nocturnal hemoglobinuria and eculizumab
Luzzatto, L., Risitano, A. M., & Notaro, R. (2010) · Haematologica · doi:10.3324/haematol.2009.017848 · Cited by 65
Detecting donor-specific antibodies: the importance of sorting the wheat from the chaff
McCaughan, J. A., Xu, Q., & Tinckam, K. J. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.01.01 · Cited by 71
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Frampton, J. E. (2020) · Drugs · doi:10.1007/s40265-020-01297-w · Cited by 71
Expanding horizons in complement drug discovery: challenges and emerging strategies
Harris, C. L. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0655-8 · Cited by 63
“Eculizumab prevents the proinflammatory impacts of C5a and MAC evident in aHUS, and prevents the MAC from lysing and activating cells in PNH; thus, blockade at the level of C5 can relieve symptoms [42].”
BackgroundMonoclonal Antibodies as Neurological Therapeutics
Gklinos, P., Papadopoulou, M., Stanulovic, V., Mitsikostas, D. D., & Papadopoulos, D. (2021) · Pharmaceuticals · doi:10.3390/ph14020092 · Cited by 61
“Eculizumab inhibits the activation of terminal complement protein (C5) pathway by binding specifically and with high affinity to C5 [29].”
BackgroundMonoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases
An, Z. (2010) · Protein & Cell · doi:10.1007/s13238-010-0052-8 · Cited by 79
“Soliris Alexion 2007 hematology PNH (chronic hemolysis) C5a humanized IgG2/IgG4 hybrid IV Rother et al., 2007”
BackgroundHuber-Lang, M. S., Barratt‐Due, A., Pischke, S. E., Sandanger, Ø., Nilsson, P. H., Nunn, M. A., Denk, S., Gaus, W., Espevik, T., & Mollnes, T. E. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400341 · Cited by 66
“This effect was mainly C5aR mediated and involved the MAPKs ERK1/2 and JNK, possibly representing key connecting molecules between the complement and TLR pathways (57).”
BackgroundInfluentialRisitano, A. M., & Marotta, S. (2018) · American Journal of Hematology · doi:10.1002/ajh.25016 · Cited by 67
Treating C3 glomerulopathy with eculizumab
Welte, T., Arnold, F., Kappes, J., Seidl, M., Häffner, K., Bergmann, C., Walz, G., & Neumann‐Haefelin, E. (2018) · BMC Nephrology · doi:10.1186/s12882-017-0802-4 · Cited by 59
“Since eculizumab is a humanized monoclonal antibody with human IgG2/IgG4 heavy and κ light chain, and mouse variable regions [42], this glomerular antibody deposition may reflect eculizumab.”
BackgroundEculizumab improves fatigue in refractory generalized myasthenia gravis
Andersen, H., Mantegazza, R., Wang, J. J., O’Brien, F., Patra, K., Howard, J. F., The REGAIN Study Group, Mazia, C. G., Wilken, M., Barroso, F. A., et al. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02148-2 · Cited by 60
“Eculizumab is a humanized monoclonal antibody that binds to complement protein C5, inhibiting the activation of the terminal complement component proteins that are believed to mediate damage at the neuromuscular junction in AChR+ gMG [2, 16].”
Paroxysmal Nocturnal Hemoglobinuria
Dezern, A. E., & Brodsky, R. A. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.01.005 · Cited by 67
“2).(63) It is the only therapy approved by the US Food and Drug Administration for PNH.”
Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
Cançado, R. D., Araújo, A. D. S., Sandes, A. F., Arrais, C., Lobo, C. L. D. C., Figueiredo, M. S., Gualandro, S. F. M., Saad, S. T. O., & Costa, F. F. (2020) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2020.06.006 · Cited by 78
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
Sampei, Z., Haraya, K., Tachibana, T., Fukuzawa, T., Shida-Kawazoe, M., Gan, S. W., Shimizu, Y., Ruike, Y., Feng, S., Kuramochi, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209509 · Cited by 61
Saccà, F., Salort‐Campana, E., Jacob, S., Cortés‐Vicente, E., & Schneider‐Gold, C. (2023) · European Journal of Neurology · doi:10.1111/ene.16180 · Cited by 56
“Eculizumab is a humanized mAb that binds to terminal C5 complement protein, prevents membrane attack complex formation, and reduces damage caused by complement-fixing AChR antibodies [18, 31, 32].”
BackgroundKelly, R., Holt, M., Vidler, J. B., Arnold, L., Large, J., Forrest, B., Barnfield, C., Pike, A., Griffin, M., Munir, T., et al. (2023) · Blood · doi:10.1182/blood.2023021762 · Cited by 56
Myasthenia gravis in 2025: five new things and four hopes for the future
Binks, S. N. M., Morse, I. M., Ashraghi, M. R., Vincent, A. C., Waters, P. J., & Leite, M. I. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12922-7 · Cited by 65
Volokhina, E. B., van de Kar, N. C. A. J., Bergseth, G., van der Velden, T. J. A. M., Westra, D., Wetzels, J. F. M., van den Heuvel, L. P., & Mollnes, T. E. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.05.018 · Cited by 55
“It is currently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and aHUS andhas opened a new era in the treatment of these diseases [18–23].”
BackgroundARGX-117, a therapeutic complement inhibiting antibody targeting C2
de Walle, I. V., Silence, K., Budding, K., de Ven, L. V., Dijkxhoorn, K., de Zeeuw, E., Yildiz, C., Gabriëls, S., Percier, J.-M., Wildemann, J., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.08.028 · Cited by 55
The modular serine proteases of the complement cascade
Forneris, F., Wu, J., & Gros, P. (2012) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2012.04.001 · Cited by 56
Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
Oyama, M., Okada, K., Masuda, M., Shimizu, Y., Yokoyama, K., Uzawa, A., Kawaguchi, N., Ikeguchi, R., Hoshino, Y., Hatano, T., et al. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420904207 · Cited by 54
Tick Salivary Compounds for Targeted Immunomodulatory Therapy
Aounallah, H., Bensaoud, C., M’ghirbi, Y., Faria, F., Chmelař, J., & Kotsyfakis, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583845 · Cited by 64
“Eculizumab, an antibody against C5, is currently prescribed for diseases characterized by excessive activation of the alternative pathway, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (123, 124).”
BackgroundEculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
Walsh, P. R., & Johnson, S. A. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-4025-0 · Cited by 53
Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
Leipold, D. D., & Prabhu, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12597 · Cited by 60
“were included, because IgG2 does not bind Fc receptors as well as IgG1, and IgG4 does not activate the complement cascade.(104) Other examples include r18D11, which blocks CD14 and is used to attenuate inflammatory responses.”
BackgroundTreatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway
Anliker‐Ort, M., Dingemanse, J., van den Anker, J., & Kaufmann, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599417 · Cited by 57
“The selective binding of eculizumab to C5 prevents C5 cleavage and subsequent formation of proinflammatory C5a and cell lysing MAC, while preserving upstream C3a- and C3b-mediated effects (114).”
BackgroundRisitano, A. M., Frieri, C., Urciuoli, E., & Marano, L. (2022) · Immunological Reviews · doi:10.1111/imr.13137 · Cited by 58
Anti-complement activity of the Ixodes scapularis salivary protein Salp20
Hourcade, D. E., Akk, A. M., Mitchell, L. M., Zhou, H., Hauhart, R. E., & Pham, C. T. N. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.11.008 · Cited by 52
Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment
Volokhina, E. B., Wijnsma, K. L., van der Molen, R. G., Roeleveld, N., van der Velden, T., Goertz, J., Sweep, F. C. G. J., Brüggemann, R., Wetzels, J. F. M., van de Kar, N. C. A. J., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.686 · Cited by 52
Evidence for the important role of inflammation in xenotransplantation
Li, J., Hara, H., Wang, Y., Esmon, C. T., Cooper, D. K. C., & Iwase, H. (2019) · Journal of Inflammation · doi:10.1186/s12950-019-0213-3 · Cited by 54
Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option
Qin, S., Dong, N., Yang, M., Wang, J., Feng, X., & Wang, Y. (2021) · Journal of Immunology Research · doi:10.1155/2021/9945725 · Cited by 56
“In the past decades, as the first FDA-approved complement inhibitor, eculizumab (C5 inhibitor) is used to treat the hemolytic disorder, paroxysmal nocturnal hemoglobinuria (PNH), which remarks an important milestone in complement drug discovery [109].”
BackgroundHolers, V. M., Rohrer, B., & Tomlinson, S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4118-2_9 · Cited by 54
Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471)
Wiles, J. A., Galvan, M. D., Podos, S. D., Geffner, M., & Huang, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191001130342 · Cited by 50
Multifaceted role of glycosylation in transfusion medicine, platelets, and red blood cells
Lee‐Sundlov, M. M., Stowell, S. R., & Hoffmeister, K. M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14874 · Cited by 51
Metadata
- Authors
- Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L.
- Affiliations
- Alexion Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Rother, Russell P
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1256-1264
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2004265876
- Cited by
- 778
- References
- 88
- Citations by year
- 2026: 34 · 2025: 38 · 2024: 43 · 2023: 58 · 2022: 34 · 2021: 47 · 2020: 59 · 2019: 49 · 2018: 42 · 2017: 52 · 2016: 60 · 2015: 39 · 2014: 41 · 2013: 38 · 2012: 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2007-12-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, paroxysmal nocturnal hemoglobinuria, complement inhibition, complement component C5, CD59, intravascular hemolysis, monoclonal antibodies, glycosylphosphatidylinositol deficiency, terminal complement activation, drug development
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Complement C5, Drug Evaluation, Preclinical, Hemoglobinuria, Paroxysmal, Humans, Drug Design, Protein Engineering, Drug Approval, Complement Inactivating Agents, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.